株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

筋肉内ドラッグデリバリー市場とパイプライン分析

Intramuscular Drug Delivery Market & Pipeline Insight

発行 PNS Pharma 商品コード 323304
出版日 ページ情報 英文 900 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
筋肉内ドラッグデリバリー市場とパイプライン分析 Intramuscular Drug Delivery Market & Pipeline Insight
出版日: 2015年01月23日 ページ情報: 英文 900 Pages
概要

筋肉内ドラッグデリバリー(薬物送達)の研究・開発は、この数十年間で製薬業界における大躍進を遂げました。高い安全性と有効性のプロファイルと精通によって、この分野における大規模投資の重要要因になっています。

当レポートでは、筋肉内ドラッグデリバリー市場について調査分析し、メカニズム、市場見通し、パイプライン、上市製品、将来見通しなどについて、体系的な情報を提供しています。

第1章 筋肉内ドラッグデリバリーとは

第2章 さまざまなドラッグデリバリーメカニズムの概要

第3章 筋肉内ドラッグデリバリーメカニズム

  • メカニズムの概要
  • 筋肉内ドラッグデリバリーデバイス

第4章 世界の筋肉内ドラッグデリバリーの市場見通し

  • 市場概要
  • 筋肉内ドラッグデリバリーのパイプラインの概要

第5章 世界の筋肉内ドラッグデリバリーの市場力学

  • 良好な市場パラメーター
  • 課題

第6章 筋肉内ドラッグデリバリー市場の将来見通し

第7章 筋肉内投与薬のパイプライン:企業別、国別、適応別、フェーズ別

  • 研究
  • 前臨床
  • 臨床
  • フェーズ0
  • フェーズI
  • フェーズI/II
  • フェーズII
  • フェーズII/III
  • フェーズIII
  • 事前登録
  • 登録済み

第8章 上市済み筋肉内投与薬:企業別、国別、適応別

第9章 臨床パイプラインにおける中止・休止中の筋肉内投与薬

  • 未開発
  • 中止
  • 市場撤退
  • 休止中

第10章 競合情勢

  • Antares Pharma
  • Eli Lily
  • Galaxo
  • HMD pharmaceuticals
  • Inovio Pharmaceuticals
  • Merck
  • Novartis
  • Pacira Pharmaceuticals
  • Pfizer
  • Pharmajet
  • Teva Pharmaceutical

図表

目次

The research and development of intramuscular drug delivery has gained significant momentum in pharmaceutical industry during past several decades. The high safety and efficacy profiles and familiarity are the most important factor for large investments in this segment. Owing to large past experience and their usage in public programs they have wide acceptance among patients due which their market is expected to be safe for investments. Pharmaceutical companies focused their efforts to churn the market by investing more funds in research and development activities. As a result, newer therapeutics are entering in global market and others are at various phases of clinical trials which are expected to enter in market in near future.

Intramuscular drug delivery market contains therapeutics belonging to different disease indication, mechanism of action and drug delivery devices. The higher sales will depend upon efficacy of newly developed intramuscular drug and marketing strategy to drive its sales. They are used for first-line therapy which they are expected to remain due to their proven pharmacological performance. The large number of patient population is expected to help the pharmaceutical companies in investigating innovative drugs during clinical trials but their market introduction will take some time before gaining success in global market.

Novel technologies are required to develop intramuscular drug delivery including both drug molecule and delivery devices. In addition to these features, new principles have to be found in coming years because most of the presently available intramuscular drug delivery systems are based on old foundations. These factors may work for many disease indications without change for several years but in case of infectious disease, oncology and autoimmune diseases novelty is required. Change in scenario is expected to have multiple effects on drug discovery and development technology along with decreasing the mortality rates. Despite variety in formulations and disease indication, stagnancy will cause severe damage to progress of global intramuscular drug delivery market.

Intramuscular drug delivery methods using molecular structures and polymers are expected to gain momentum in coming years. More structural, physical and biochemical improvements have to take place to increase their marketing potential. Underlying principles behind these materials are being discovered to increase their pharmacological benefits for future usage. Gels are another material required for future development better and efficient delivery of intramuscular drug to the patients. The capabilities of sustained release have been found to be associated with these materials which are expected to make sustainable market place in near future. Researchers are developing new materials with better biodegradability and sustained release capabilities for providing efficient intramuscular drug delivery.

With the recent technological advances, it is expected that newer methods for intramuscular drug delivery will be developed and commercialized in coming years. Market size of these materials and methods is modest which is expected to steady growth but before doing so they have to improve a lot before becoming marketable. Many novel intramuscular drugs are at various phases of clinical trials which are expected to be available after some time. Pharmaceutical companies have already identified the opportunities involved in the development of intramuscular drugs and many of them are at advanced phases of clinical trials. They are supposed to be cost effective along with pharmacologically efficient and minimized side effects.

"Intramuscular Drug Delivery Market & Pipeline Insight" Report Findings:

  • Intramuscular Drug Delivery Mechanism
  • Global Intramuscular Drug Delivery Market Outlook
  • Intramuscular Drug Pipeline by Company, Country, Indication & Phase
  • Intramuscular Drug Pipeline: 364 Drugs
  • Marketed Intramuscular Drugs: 186 Drugs
  • Majority Drugs in Phase-I Trials:108
  • Global Intramuscular Drug Delivery Market Future Prospects

Table of Contents

1. Introduction to Intramuscular Drug Delivery

2. Overview of Different Drug Delivery Mechanisms

3. Intramuscular Drug Delivery Mechanism

  • 3.1 Mechanism Overview
  • 3.2 Intramuscular Drug Delivery Devices

4. Global Intramuscular Drug Delivery Market Outlook

  • 4.1 Market Overview
  • 4.2 Intramuscular Drug Delivery Pipeline Overview

5. Global Intramuscular Drug Delivery Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Challenges

6. Intramuscular Drug Delivery Market Future Prospects

7. Intramuscular Drug Pipeline by Company, Country, Indication & Phase

  • 7.1 Research
  • 7.2 Preclinical
  • 7.3 Clinical
  • 7.4 Phase-0
  • 7.5 Phase-I
  • 7.6 Phase-I/II
  • 7.7 Phase-II
  • 7.8 Phase-II/III
  • 7.9 Phase-III
  • 7.10 Preregistration
  • 7.11 Registered

8. Marketed Intramuscular Drugs by Company, Country & Indication

9. Discontinued & Suspended Intramuscular Drugs in Clinical Pipeline

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Market Withdrawal
  • 9.4 Suspended

10. Competitive Landscape

  • 10.1 Antares Pharma
  • 10.2 Eli Lily
  • 10.3 Galaxo
  • 10.4 HMD pharmaceuticals
  • 10.5 Inovio Pharmaceuticals
  • 10.6 Merck
  • 10.7 Novartis
  • 10.8 Pacira Pharmaceuticals
  • 10.9 Pfizer
  • 10.10 Pharmajet
  • 10.11 Teva Pharmaceutical
  • Figure 1-1: Site of Intramuscular Drug Delivery
  • Figure 1-2: Various Methods of Drug Delivery
  • Figure 1-3: Features of Intramuscular Drug Delivery System
  • Figure 1-4: Classification of Human Muscular System
  • Figure 1-5: Intramuscular Drug Delivery Sites for Administration
  • Figure 1-6: Technical Issues with Intramuscular Drug Delivery
  • Figure 3-1: Factors Affecting Intramuscular Drug Activity
  • Figure 3-2: Mechanism of Intramuscular Drug Delivery
  • Figure 3-3: Properties of Intramuscular Drug Delivery
  • Figure 4-1: Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-2: Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 4-3: No Development Reported Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-4: No Development Reported Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 4-5: Discontinued Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-6: Discontinued Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 4-7: Suspended Intramuscular Pipeline by Phase (%), 2015
  • Figure 4-8: Suspended Intramuscular Pipeline by Phase (Numbers), 2015
  • Figure 5-1: Drivers for Intramuscular Drug Delivery Market
  • Figure 5-2: Challenges for Intramuscular Drug Delivery
  • Table 2-1: Overview of Different Drug Delivery Mechanisms
  • Table 3-1: Comparative Analysis of Intramuscular Drug Delivery Devices
Back to Top